Skip to main content

The role of LDN in cancer management.


Prof Angus Dalgleish, MD


Analysis of available clinical data either alone or in combination with chemotherapy, and how does its known activity affecting both opiate and TLR receptors support further development.

Session Learning Objective

How known mechanisms of action can explain reported anticancer activities and how best to take this into clinical studies for registration.


Clinical review.

Mechanisms of Action (MOA) review

Discussion of how to take this further.